Key Facts:
Eli Lilly is an American multinational pharmaceutical company headquartered in Indianapolis in Indiana.
The products of the company are sold in 125 countries.
Prime Highlights:
Mounjaro targets both GIP and GLP-1 receptors, offering a unique mechanism to aid weight loss and improve glycemic control.
Approved for adults with obesity (BMI ≥ 30 kg/m²), overweight (BMI ≥ 27 kg/m²) with at least one comorbidity, and type 2 diabetes as a supplement to diet and exercise.
Key Background:
Eli Lilly and Company has officially introduced Mounjaro (tirzepatide) in India following approval from the Central Drugs Standard Control Organization (CDSCO). This innovative once-weekly injectable therapy is designed to aid in chronic weight management and improve the treatment of type 2 diabetes, offering a unique mechanism of action by targeting both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.
Mounjaro is the first therapy of its kind, utilizing dual incretin receptor activation to facilitate weight loss and enhance glycemic control. It is indicated for individuals with obesity (Body Mass Index (BMI) of 30 kg/m² or greater), overweight (BMI of 27 kg/m² or greater) with at least one related comorbidity, and type 2 diabetes. The medication is prescribed alongside a reduced-calorie diet and increased physical activity.
India’s growing prevalence of obesity and type 2 diabetes, with over 101 million diabetes cases and nearly 100 million individuals affected by obesity, highlights the urgent need for innovative treatments. Eli Lilly aims to address this dual burden with Mounjaro, which has shown efficacy in global clinical trials such as SURMOUNT-1 and SURPASS, demonstrating its ability to reduce weight, improve glycemic control, and regulate appetite.
Dr. Manish Mistry, Senior Medical Director at Lilly India, emphasized that the introduction of Mounjaro represents a significant step forward in metabolic health management, providing a vital tool for healthcare professionals in addressing the challenges of obesity and diabetes. The launch of Mounjaro marks a significant milestone for Eli Lilly in its commitment to improving healthcare outcomes and advancing patient care in India.
Read More – Click Here
